

## DAFTAR PUSTAKA

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2021;71(3):209-49.
2. Jicman D, Niculet E, Lungu M, Onisor C, Rebegea L, Vesa D, et al. Nasopharyngeal carcinoma: A new synthesis of literature data (Review). *Exp Ther Med.* 2022;23(136):1-7.
3. Wei L, Shi C, Zhang Y. Expression of miR-34a and Ki67 in nasopharyngeal carcinoma and the relationship with clinicopathological features and prognosis. *Oncol Lett.* 2020;19:1273–80.
4. Eriza, Kurnia E, Utama DS. Correlation Of Ki67 Level To Metastatic Events In Nasopharyngeal Carcinoma. *Int J Nasopharyngeal Carcinoma.* 2020;2(2):31-4.
5. EI-Naggar AK. *WHO Classification of Head and Neck Tumours.* In: Chan JKC, Grandis JR, Takata T, Slootweg PJ, editors. Tumours of the nasopharynx. 4 ed. France: International Agency for Research on Cancer 2017. p. 63-5.
6. Chen Y-P, Chan ATC, Le Q-T, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. *Lancet.* 2019;6(394):64–80.
7. Hamid GA. Pharynx-Diagnosis and Treatment. *Epidemiology and Outcomes of Nasopharyngeal Carcinoma.* London: British Library Cataloguing; 2021. p. 43-51.
8. GLOBOCAN. Indonesia. *IARC WHO.* 2020:1-2.
9. Jodie RM, Rahman S. Gambaran Terapi dan Respon Terapi Karsinoma Nasofaring di RSUP Dr. M. Djamil Padang. *Jurnal Otorinolaringologi Kepala dan Leher Indonesia.* 2022;1(1):1-7.
10. Li Y, Yue L, Li Y, Zhang Q, Liang X. Prognostic value of Ki-67 in nasopharyngeal carcinoma: a meta-analysis. *Biosci Rep.* 2021;41:1-10.
11. Alsafadi N, Alqarni M, Attar M, Mgarry R, Bokhari A. Nasopharyngeal Cancer: Prevalence, Outcome, and Impact on Health-Related Quality of Life at Princess Norah Oncology Center, Jeddah, Saudi Arabia. *Cureus.* 2020;12(5):1-9.
12. Tian Y, Tang L, Yi P, Pan Q, Han Y, Shi Y, et al. MiRNAs in radiotherapy resistance of nasopharyngeal carcinoma. *J Cancer.* 2020;11(13):3976-85.
13. Chen W, Hu G-H. Biomarkers for enhancing the radiosensitivity of nasopharyngeal carcinoma. *Cancer Biol Med.* 2015;12(1):23-32.
14. Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). *Eur J Cancer.* 2009;45(2):228-47.
15. Tirkes T, Hollar MA, Tann M, Kohli MD, Akisik F, Sandrasegaran K. Response criteria in oncologic imaging: review of traditional and new criteria. *Radiographics.* 2013;33(5):1323-41.
16. Kuhuwael FG, Perkasa MF, Miskad UA, Punagi AQ, Said FA. Comparison of the means of argyrophilic nucleolar organizer region (mAgNOR) pre-and post-

- therapy in nasopharyngeal carcinoma patients at Wahidin Sudirohusodo General Hospital Makassar. *Indones Biomed J*. 2016;8(2):103-8.
17. Fulawka L, Blaszczyk J, Tabakov M, Halon A. Assessment of Ki-67 proliferation index with deep learning in DCIS (ductal carcinoma in situ). *Sci Rep*. 2022;12(3166):1-12.
  18. Shi P, Zhong J, Hong J, Huang R, Wang K, Chen Y. Automated Ki-67 quantification of immunohistochemical staining image of human nasopharyngeal carcinoma xenografts. *Sci Rep*. 2016;6:1-9.
  19. Adham M, Gondhowiardjo S, Soediro R, Jack Z, Lisnawati, Witjaksono F, et al. Panduan Penatalaksanaan Kanker Nasofaring. *KPKN KEMENKES RI*. 2016:1-8.
  20. Nugroho P, Yusuf M, Hidayati T. Correlation between Cell Proliferation with Cervical Lymphoid Node Status in Nasopharyngeal Carcinoma Patients. *Folia Medica Indones*. 2021;57(1):20-6.
  21. Syukri NA, Fidiawati WA, Tripriadi ES. Profil Pemeriksaan Indeks Proliferatif Ki-67 pada Penderita Kanker Payudara di RSUD Arifin Achmad Tahun 2010-2015. *JOM FK*. 2016:1-13.
  22. Rezano A, Pan CE, Istiqomah AA, Zada A. Association of Ki-67 Expression and Response of Neoadjuvant Chemotherapy in Invasive Breast Cancer Patients in Bandung. *Int J Integr Health Sci*. 2018;6(2):80-3.
  23. Smits HJ, Ruiter LN, Breimer GE, Willems SM, Philippens ME. Using Intratumor Heterogeneity of Immunohistochemistry Biomarkers to Classify Laryngeal and Hypopharyngeal Tumors Based on Histologic Features. *Mod Pathol*. 2023;36(8):1-10.
  24. Pan D, Wei K, Ling Y, Su S, Zhu M, Chen G. The prognostic role of Ki-67/MIB-1 in cervical cancer: a systematic review with meta-analysis. *Med Sci Monit*. 2015;21:882-9.
  25. Wang D, Chen D, Zhang C, Chai M, Guan M, Wang Z, et al. Analysis of the relationship between Ki-67 expression and chemotherapy and prognosis in advanced non-small cell lung cancer. *Transl Cancer Res*. 2020;9(5):1-14.
  26. Denkert C, Loibl S, Müller B, Eidtmann H, Schmitt W, Eiermann W. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. *Ann Oncol Off J Eur Soc Med Oncol*. 2013;11(24):2786-93.
  27. Fasching PA, Heusinger K, Haeberle L, Niklos M, Hein A, Bayer CM, et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. *BMC Cancer*. 2011;11(486):1-13.
  28. Wajid S, Samad FA, Syed AS, Kazi F, Samad FA, Syed AS. Ki-67 and its relation with complete pathological response in patients with breast cancer. *Cureus*. 2021;13(7):1-8.
  29. Lindsay C, Le Moulec S, Billiot F, Loriot Y, Ngo-Camus M, Vielh P, et al. Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer. *BMC cancer*. 2016;16(1):1-11.
  30. Liu Q, Ran D, Wang L, Feng J, Deng W, Mei D, et al. Association between Ki67 expression and therapeutic outcome in colon cancer. *Oncol Lett*. 2023;25(6):1-6.

31. Cahyanur R, Irawan C, Yunus RE, Adham M. Expression levels of Ki-67 and cyclin D1 in advanced nasopharyngeal carcinoma and its prognosis. *Biomed.* 2023;43(01):492-8.
32. Okabe M, Inagaki H, Murase T, Inoue M, Nagai N, Eimoto T. Prognostic significance of p27 and Ki-67 expression in mucoepidermoid carcinoma of the intraoral minor salivary gland. *Mod Pathol.* 2001;14(10):1008-14.
33. Childs A, Kirkwood A, Edeline J, Luong TV, Watkins J, Lamarca A. Ki-67 index and response to chemotherapy in patients with neuroendocrine tumours. *Endocr Relat Cancer.* 2016;23(7):563–70.
34. AmericanCancerSociety. About Nasopharyngeal Cancer. *cancerorg.* 2019:1-9.
35. Tsang RK-Y, Kwong DL-W. Nasopharyngeal Carcinoma. In: Watkinson JC, Clarke RW, editors. *Scott-Brown's Otorhinolaryngology Head and Neck Surgery.* 3. 8 ed. Boca Raton: Taylor & Francis Group; 2019. p. 93–114.
36. GLOBOCAN. Nasopharynx. *IARC WHO.* 2021:1-2.
37. Pangribowo S. Beban Kanker di Indonesia. *InfoDATIN KEMENKES.* 2019:1-12.
38. Utama DS, Eriza, Wahyuni I, Akbar A. The Characteristics Of Nasopharyngeal Carcinoma Patients In Moehammad Hoesin General Hospital Palembang January 2013 - December 2017. *Int J Nasopharyngeal Carcinoma.* 2019;1(1):30-2.
39. Nour AS, Weldehawariat TD, Woldemariam AA, Layo DG. Nasopharyngeal Carcinoma: A Retrospective Study on Imaging Patterns at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. *Ethiop J Health Sci.* 2020;30(2):215–22.
40. Salehiniya H, Mohammadian M, Hashejani A, Mahdavifar N. Nasopharyngeal Cancer in the World: Epidemiology, Incidence, Mortality and Risk Factors. *World Cancer Res J.* 2018;5(1):1-8.
41. Kurniawan A. *DNA Metilasi & Kanker Nasofaring.* Jember: Jagat Litera; 2022. p. 1-103.
42. Wu L, Li C, Pan L. Nasopharyngeal carcinoma: A review of current updates. *Exp Ther Med.* 2018;15:3687–92.
43. Zhu QY, Zhao GX, Li Y, Talakatta G, Mai HQ, Le QT, et al. *Advances in pathogenesis and precision medicine for nasopharyngeal carcinoma.* In: Zhu QY, Zhao GX, Li Y, editors. MedComm. 2. China: Wiley; 2021. p. 175-206.
44. Zeng M-S, Zeng Y-X. *Pathogenesis and etiology of nasopharyngeal carcinoma.* In: U JJ, Cooper JS, Lee AWM, editors. Nasopharyngeal Cancer: Multidisciplinary Management. Berlin, Heidelberg: Springer; 2010. p. 9-25.
45. Tulalamba W, Janvilisri T. Nasopharyngeal carcinoma signaling pathway: an update on molecular biomarkers. *Int J Cell Biol.* 2012:1-10.
46. Tsang C, Lo K, Nicholls JM, Huang S, Tsao S. *Pathogenesis of Nasopharyngeal Carcinoma: Histogenesis, Epstein–Barr Virus Infection, and Tumor Microenvironment.* In: Lee AWM, Lung ML, Ng WT, editors. Nasopharyngeal Carcinoma. China: Elsevier; 2019. p. 45-64.
47. Siak PY, Heng WS, Teoh SSH, Lwin YY, Cheah S-C. Precision medicine in nasopharyngeal carcinoma: comprehensive review of past, present, and future prospect. *J Transl Med.* 2023;21:2-60.

48. Sun X. Ki-67 Regulates Cell Cycle Progression and Heterochromatin Organization. *escholarshipumassmededu* 2017:1-178.
49. Almobarak AA, Jebreel AB, Abu-Zaid A. Molecular Targeted Therapy in the Management of Recurrent and Metastatic Nasopharyngeal Carcinoma: A Comprehensive Literature Review. *Cureus*. 2019;11(3):1-13.
50. Lee A, Lydiatt W, Colevas D, Glastonbury C. Nasopharyng. *AJCC Cancer Staging Manual*. Chicago: Springer; 2017. p. 104-15.
51. Guo Rui M, Yan-Ping Mao M, Ling-Long Tang M, Lei Chen M, Ying Sun M, Jun Ma M. The Evolution of Nasopharyngeal Carcinoma Staging. *Br J Radiol*. 2019;92.
52. Chua M, Wee J, Hui E, Chan A. Nasopharyngeal carcinoma. *Lancet*. 2016;387:1012–24.
53. Eniola E, Bola A, Pelumi O-P, Dubem U, Mike I, Babatunde O. Nasopharyngeal Carcinoma: Profile, Challenges and 5-Year Outcome in a Nigerian Tertiary Hospital. *Int J Healthc Med Sci*. 2018;4(2):25-30.
54. Ye J-X, Liang X, Wei J, Zhou J, Liao Y, Tang X-Q. Compliance with National Guidelines on the Treatment of Stage II–IVB Nasopharyngeal Carcinoma in a Regional Cancer Center of Southern China. *Asian Pac J Cancer Prev*. 2018;19:115-20.
55. Dwijayanti F, Prabawa A, Besral, Herawati C, Oncology. The Five-Year Survival Rate of Patients with Nasopharyngeal Carcinoma Based on Tumor Response after Receiving Neoadjuvant Chemotherapy, Followed by Chemoradiation, in Indonesia: A Retrospective Study. *Oncology* 2020;98(3):154-60.
56. Dou H, Hu D, Lam C, Liu Y, Wang X, Zhang W. Retrospective analysis of results of treatment for nasopharyngeal carcinoma in Macao. *Chin J Cancer Res*. 2014;26(2):1-11.
57. Feryel L, Yosra B, Mouna A, Khadija M, Amina M, Yosra Y, et al. Complete clinical response after induction chemotherapy followed by chemoradiotherapy in nasopharyngeal carcinoma: impact on oncologic outcomes. *Chemotherapy*. 2017;1:1-8.
58. Peng H, Chen L, Zhang Y, Li W-F, Mao Y-P, Liu X, et al. The tumour response to induction chemotherapy has prognostic value for long-term survival outcomes after intensity-modulated radiation therapy in nasopharyngeal carcinoma. *Sci Rep*. 2016;6(1):1-9.
59. Chalian H, Töre H, Horowitz J, Salem R, Miller F, Yaghmai V, et al. Radiologic assessment of response to therapy: Comparison of recist versions 1.1 and 1.0. *Radiographics*. 2011;31(7):2093–106.
60. WHO. Reporting of response. *WHO Handbook For Reporting Results Of Cancer Treatment*. Geneva: WHO Offset Publication; 1979. p. 22-4.
61. Jahan SI, Badruddoza SM, Asafudullah S, Amin MN. Expression of Ki-67 and Its Association with Histological Type, Grade and Stage of Colorectal Carcinoma. *Ibrahim Card Med J*. 2020;10(1-2):33-9.

62. Nabi U, Nagi A, Sami W. Ki-67 proliferating index and histological grade, type and stage of colorectal carcinoma. *J Ayub Med Coll Abbottabad*. 2008;20(4):44-8.
63. Cuylen S, Blaukopf C, Politi AZ, Müller-Reichert T, Neumann B, Poser I, et al. Ki-67 acts as a biological surfactant to disperse mitotic chromosomes. *Nature*. 2016;535:308-12.
64. Menon S, Guruvayoorappan C, Sakthivel K, Rasmi R, . Ki-67 protein as a tumour proliferation marker. *Clin Chim Acta*. 2019;491:39-45.
65. Matthews HK, Bertoli C, de Bruin RA. Cell cycle control in cancer. *Nat Rev Mol Cell Biol*. 2022;23(1):74-88.
66. Usman H, Abidin F. Digital image analysis of immunohistochemistry KI-67 using QuPath software in breast cancer. *J Kedokt dan Kesehat Indones*. 2021;30(12):34-43.
67. Li LT, Jiang G, Chen Q, Zheng JN. Ki67 is a promising molecular target in the diagnosis of cancer (Review). *Mol Med Rep*. 2015;11:1566-72.
68. Pai R, Karki S, Agarwal R, Sieber S, Barasch S. Optimal settings and clinical validation for automated Ki67 calculation in neuroendocrine tumors with open source informatics (QuPath). *J Pathol Inform*. 2022;13:1-5.
69. Geread R, Morreale P, Dony R, Brouwer E, Wood G, Androutsos D, et al. IHC Color Histograms for Unsupervised Ki67 Proliferation Index Calculation. *Front Bioeng Biotechnol*. 2019;7:1-20.
70. Asri A, Mayorita P, Khambri D. Hubungan Ekspresi Ki-67 Dengan Karakteristik Histopatologik Pada Kanker Payudara Tripel Negatif. *Majalah Kedokteran Andalas*. 2015;38(3):165-72.
71. Stec R, Cierniak S, Lubas A, Brzóskowska U, Syryło T, Zieliński H, et al. Intensity of nuclear staining for Ki-67, p53 and survivin as a new prognostic factor in non-muscle invasive bladder cancer. *Pathol Oncol Res*. 2020;26:1211-9.
72. Yunokawa M, Yoshida H, Watanabe R, Noguchi E, Shimomura A, Shimoi T, et al. Allred score is a promising predictor of prognosis and medroxyprogesterone acetate efficacy in patients with endometrial cancer. *Cancer Chemother Pharmacol*. 2017;80:127-34.
73. Zhang J, Liu Y, Deng Y, He J, Lang J. Ki67 And Nm23 Are Potential Prognostic Markers In Patients With Nasopharyngeal Carcinoma. *Int J Clin Exp Pathol*. 2016;9(6):6350-6.
74. Sawali H, Yunus MRM, Ai OC, Athar PPSH. Cutaneous Metastases from Nasopharyngeal Carcinoma: A Rare Manifestation. *PJOHNS*. 2010;25(2):32-5.
75. Lu Y, Huang H, Kang M, Yi M, Yang H, Wu S. Combined Ki67 and ERCC1 for prognosis in non-keratinizing nasopharyngeal carcinoma underwent chemoradiotherapy. *Oncotarget*. 2017;8:1-11.
76. Dahlan MS. *Menggunakan Rumus Besar Sampel secara Benar*. In: Dahlan MS, editor. *Besar Sampel dan Cara Pengambilan Sampel dalam Penelitian*. 5 ed. Jakarta: Salemba Medika; 2019. p. 80-1.
77. Raymos A, Boesoirie SF, Dewi YA. *Epidemiology Of Nasopharyngeal Carcinoma: Understanding The Interplay Of Genetic And Environmental*

- Factors*. Proceedings of the 19th Otorhinolaryngology Head and Neck Surgery National Congress (PERHATIKL 2022). 68: Springer Nature; 2023. p. 212-17.
78. Mahdavifar N, Ghoncheh M, Mohammadian-Hafshejani, Khosravi B, Salehiniya H. Epidemiology and Inequality in the Incidence and Mortality of Nasopharynx Cancer in Asia. *Osong Public Health Res Perspect* 2016;7(6):360-72.
  79. Sinha S, Gajra A. *Nasopharyngeal Cancer*. In: Sinha S, Winters R, Gajra A, editors. A service of the National Library of Medicine, National Institutes of Health. Treasure Island (FL): StatPearls Publishing; 2022. p. 1-20.
  80. Zhang R, He Y, Wei B, Lu Y, Zhang J, Zhang N, et al. Nasopharyngeal Carcinoma Burden and Its Attributable Risk Factors in China: Estimates and Forecasts from 1990 to 2050. *Int J Environ Res Public Health* 2023;20(2926):1-12.
  81. Faiza S, Rahman S, Asri A. Karakteristik Klinis dan Patologis Karsinoma Nasofaring di Bagian THT-KL RSUP Dr.M.Djamil Padang. *J Kesehat Andalas*. 2016;5(1):90-6.
  82. Guo X, Johnson RC, Deng H, Liao J, Guan L, Nelson GW, et al. Evaluation of nonviral risk factors for nasopharyngeal carcinoma in a high-risk population of Southern China. *Int J Cancer*. 2009;124(4):2942-7.
  83. Safavi-Naini A, Raad N, Ghorbani J, Chaibakhsh S, Daryasar RR. Incidence Trends and Geographical Distribution of Nasopharyngeal Carcinoma in Iran. 2009:24-. *Iran J Cancer Prev*. 2015;8(1):24-8.
  84. Adham M, Kurniawan AN, Muhtadi AI, Roezin A, Hermani B, Gondhowiardjo S, et al. Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. *Chin J Cancer Res*. 2012;31(4):185-96.
  85. Setiani L, Kurnia B, Karnita Y. Characteristics Of Nasopharyngeal Carsinoma In Children And Adolescents In Dr. Zainoel Abidin General Hospital Banda Aceh. *International Journal Of Nasopharyngeal Carcinoma*. 2019;1(03):93-6.
  86. Astant N. *Karakteristik penderita karsinoma nasofaring pada pasien rawat jalan di Rumah Sakit Umum Pusat Dr. Wahidin Sudirohusodo periode Juni 2016-Juni 2017* In: Astant N, editor.: Universitas Hasanuddin Fakultas Kedokteran Makassar; 2017. p. 32-8.
  87. Soraya H, Triwulandari E. *Association Of Educational Level And Alcohol Consumption In Patients With Nasopharyngeal In Dental Clinic RSCM Jakarta Between 2006-2009*. *Jurnal Universitas Indonesia*. 2013:1-16.
  88. Handayani R, Dewi YA, Madani DZ. Prevalence of nasopharyngeal carcinoma patients in departement of ORL-HNS Hasan Sadikin general hospital 2010-2017. *International journal of nasopharyngeal carcinoma*. 2020;2(01):1-3.
  89. Li WZ, Liu GY, Lv SH, Xu SK, Liang H, Liu KY, et al. Educational disparities in nasopharyngeal carcinoma survival: Temporal trends and mediating effects of clinical factors *Clin Transl Med* 2020. 2020;e134:1-4.
  90. Zhu GL, Zhang XM, Yang KB, Tang LL, Ma J. Metastatic patterns of level II-V cervical lymph nodes assessed per vertebral levels in nasopharyngeal carcinoma. *Radiat Oncol J*. 2023;179:1-7.
  91. Lin Y, Chen J, Wang X, Chen S, Yang Y, Hong Y, et al. An overall survival predictive nomogram to identify high-risk patients among locoregionally

- advanced nasopharyngeal carcinoma: Developed based on the SEER database and validated institutionally. *Front Oncol.* 2023;13:1-11.
92. Rahman S, Subroto H, Novianti D. *Clinical Presentation of Nasopharyngeal Carcinoma in West Sumatra, Indonesia.* The 20th World Congress of IFOS2013. p. 1-2.
  93. Dawolo AP, Utama DS, Kasim BI. Profil klinis karsinoma nasofaring di Departemen THTKL RSUP Dr. Mohammad Hoesin Palembang tahun 2014-2015. *Maj Kedokt Sriwij.* 2019;49(1):1-9.
  94. Irawan C, Rachman A, Rahman P, Mansjoer A. Role of pretreatment hemoglobin to platelet ratio in predicting survival outcome of locally advanced nasopharyngeal carcinoma patients. *J Cancer Epidemiol.* 2021;2021(1103631):1-7.
  95. Melani W, Sofyan F. Karakteristik penderita kanker nasofaring di Rumah Sakit H. Adam Malik Medan Tahun 2011. *E-Jurnal FK-USU.* 2013;1(1):1-5.
  96. Swain SK, Samal S, Mohanty JN, Choudhury J. Nasopharyngeal carcinoma among the pediatric patients in a non-endemic region: our experience at a tertiary care teaching hospital in Eastern India. *Egypt J Pediatr.* 2020;68(1):1-6.
  97. Jin X, Hu R, Guo H, Ding C, Pi G, Tian M. Pretreatment Body Mass Index (BMI) as an independent prognostic factor in nasopharyngeal carcinoma survival: A systematic review and meta-analysis. *Nutr Cancer.* 2022;74(10):3457-67.
  98. Huang P-Y, Wang C-T, Cao K-J, Guo X, Guo L, Mo H-Y, et al. Pretreatment body mass index as an independent prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy: findings from a randomised trial. *Eur J Cancer.* 2013;49(8):1923-31.
  99. Li W, Shen LJ, Chen T, Sun XQ, Zhang Y, Wu M, et al. Overweight/obese status associates with favorable outcome in patients with metastatic nasopharyngeal carcinoma: a 10-year retrospective study. *Cancer Communications.* 2016;35(1):1-9.
  100. Wulandari Y, Satyani M, Marino M, Manikam NRM. Body Mass Index And Survival Rate in Nasopharyngeal Cancer Patient: An Evidence-based Case Report. *World Nutr J.* 2020;3(2):38-44.
  101. Vergeer MR, Doornaert PA, Rietveld DH, Leemans CR, Slotman BJ, Langendijk JA. Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program. *Int J Radiat Oncol Biol Phys.* 2009;74(1):1-8.
  102. Lin Y-H, Chang K-P, Lin Y-S, Chang T-S. Evaluation of effect of body mass index and weight loss on survival of patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy. *Radiat Oncol J.* 2015;10:1-9.
  103. OuYang PY, Zhang LN, Tang J, Lan XW, Xiao Y, Gao YH, et al. Evaluation of body mass index and survival of nasopharyngeal carcinoma by propensity-matched analysis: an observational case-control study. *Medicine.* 2016;95(2):1-7.

104. Dewi YA, Fakhrizal A, Boesoirie SF, Saputri AH. Nutritional Status of Patients with Nasopharyngeal Carcinoma. *Open Access Maced J Med Sci.* 2021;9(B):1435-39.
105. Wu W, Jiang G, Xu Z, Wang R, Pan A, Gao M, et al. Three-dimensional pulsed continuous arterial spin labeling and intravoxel incoherent motion imaging of nasopharyngeal carcinoma: correlations with Ki-67 proliferation status. *Quant Imaging Med Surg.* 2021;11(4):1394-405.
106. Zhao L, Chen H, Hu B, Zhang H, Lin Q. Prognostic significance of Ki67 expression and the derived neutrophil-lymphocyte ratio in nasopharyngeal carcinoma. *Cancer Manag Res.* 2018:1919-26.
107. Airoidi M, Garzaro M, Valente G, Mamo C, Bena A, Giordano C, et al. Clinical and biological prognostic factors in 179 cases with sinonasal carcinoma treated in the Italian Piedmont region. *Oncology.* 2009;76:262-9.
108. Shi Z, Jiang W, Chen X, Xu M, Wang X, Zha D. Prognostic and clinicopathological value of Ki-67 expression in patients with nasopharyngeal carcinoma: a meta-analysis. *Ther Adv Med Oncol.* 2020;12:1-11.
109. Humphries M, Maxwell P, Salto-Tellez M. QuPath: The global impact of an open source digital pathology system. *Comput Struct Biotechnol J.* 2021;19:852-9.
110. Wildeman MA, Fles R, Herdini C, Rai S, Indrasari, Vincent AD, et al. Primary treatment results of Nasopharyngeal Carcinoma (NPC) in Yogyakarta, Indonesia. *PloS one.* 2013;8(5):1-6.
111. Li WZ, Lv X, Hu D, Lv SH, Liu GY, Liang H, et al. Effect of induction chemotherapy with paclitaxel, cisplatin, and capecitabine vs cisplatin and fluorouracil on failure-free survival for patients with stage IVA to IVB nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical trial. *JAMA Oncol* 2022;8(5):706-14.
112. Haleshappa RA, Thanky AH, Kuntegowdanahalli L, Kanakasetty GB, Dasappa L, Jacob L. Epidemiology and outcomes of nasopharyngeal carcinoma: Experience from a regional cancer center in Southern India. *South Asian J Cancer.* 2017;6(3):122-4.
113. Perri F, Scarpati GDV, Buonerba C, Di Lorenzo G, Longo F, Muto P, et al. Combined chemo-radiotherapy in locally advanced nasopharyngeal carcinomas. *World J Clin Oncol.* 2013;4(2):47-51.
114. Cao X, Song J, Xu J, Gong G, Yang X, Su Y, et al. Tumor blood flow is a predictor of radiotherapy response in patients with nasopharyngeal carcinoma. *Front Oncol.* 2021;11:1-11.
115. Sarma G, Paul M, Nath J, Medhi PP, Bhattacharyya M, Kalita AK. Clinical outcomes and prognostic factors of locally advanced nasopharyngeal cancer treated with intensity modulated radiotherapy: first experience report from Northeast India. *Indian J Otolaryngol Head Neck Surg.* 2022;74(Suppl 3):5964-73.
116. Chen J, Liu T, Sun Q, Hu F. Clinical and prognostic analyses of 110 patients with N3 nasopharyngeal carcinoma. *Medicine.* 2018;97(49):1-8.



117. Susanto SA, Dewi YA, Saputri RAH. Assessment of Response to Chemoradiation and Radiation Therapy in Patients with Nasopharyngeal Carcinoma. *Open Access Maced J Med Sci.* 2022;10(B):2307-12.
118. Lian CL, Zhou R, Zhou Y, Zhou P, Wu S-G. Assessment of Response to Different Induction Chemotherapy Regimens in Locally Advanced Nasopharyngeal Carcinoma. *Drug Des Devel Ther.* 2023;551-62.
119. Guo YM, Chen JR, Feng YC, Chua ML, Zeng Y, Hui EP, et al. Germline polymorphisms and length of survival of nasopharyngeal carcinoma: an exome-wide association study in multiple cohorts. *Adv Sci.* 2020;7(10):1-13.
120. Jogie JA, Maharaj A, Mahase T, Bhagwandeem S, Ramcharan L, Mohammed R, et al. A Preliminary Analysis of Ki-67 Expression in Breast Cancer in the Caribbean. *Cureus.* 2023;15(4):1-8.
121. Alba E, Lluch A, Ribelles N, Anton-Torres A, Sanchez-Rovira P, Albanell J, et al. High proliferation predicts pathological complete response to neoadjuvant chemotherapy in early breast cancer. *The oncologist.* 2016;21(2):150-5.
122. Siti-Azrin AH, Norsa'adah B, Naing NN. Prognostic factors of nasopharyngeal carcinoma patients in a tertiary referral hospital: a retrospective cohort study. *BMC Res Notes.* 2017;10(705):1-7.
123. Islam KA, Chow LK-Y, Kam NW, Wang Y, Chiang CL, Choi HC-W, et al. Prognostic biomarkers for survival in nasopharyngeal carcinoma: A systematic review of the literature. , 14(9), 2122. *Cancers.* 2022;14(2122):1-14.
124. Chiang CL, Guo Q, Ng WT. Prognostic factors for overall survival in nasopharyngeal cancer and implication for TNM staging by UICC: A systematic review of the literature. *Front Oncol.* 2021;11:1-19.
125. Xing H-J, Chen X-D, Sun H-X, Dai Y-Z, Han Y-F, Chen H-B, et al. The Relevance of regenerating gene 1a polymorphisms to radiation sensitivity and survival of nasopharyngeal carcinoma receiving radiotherapy in a Southern Chinese Population. *Pharmgenomics Pers Med.* 2021:1403-13.
126. López-Flores LA, Pérez-Rubio G, Falfán-Valencia R. Distribution of polymorphic variants of CYP2A6 and their involvement in nicotine addiction. *EXCLI journal.* 2017;16:174-96.
127. Cho WC-s. Nasopharyngeal carcinoma: molecular biomarker discovery and progress. *Molecular cancer.* 2007;6:1-9.
128. Catarino RJ, Breda E, Coelho V, Pinto D, Sousa H, Lopes C, et al. Association of the A870G cyclin D1 gene polymorphism with genetic susceptibility to nasopharyngeal carcinoma. *Head Neck-J SCI SPEC.* 2006;28(7):603-8.
129. Chen J, Fu L, Zhang L-Y, Kwong DL, Yan L, Guan X-Y. Tumor suppressor genes on frequently deleted chromosome 3p in nasopharyngeal carcinoma. *Chin J Cancer.* 2012;31(5):215-22.
130. Li W, Yu S, Duan X, Yao S, Tang L, Cheng H. COMT rs737865 mediates chemobrain in breast cancer patients with various levels of Ki-67. *Am J Cancer Res.* 2022;12(7):3185-97.
131. Uxa S, Castillo-Binder P, Kohler R, Stangner K, Müller GA, Engeland K. Ki-67 gene expression. *Cell Death Differ.* 2021;28(12):3357-70.

132. Wang Y. LRRC3B polymorphisms contributed to breast cancer susceptibility in Chinese Han Population. *Front Oncol.* 2021;11:1-10.
133. Benzeid R, Ghibid A, Tawfiq N, Benchakrou N, Bendahhou K, Benider A, et al. Genetic Polymorphisms in ERCC1 Gene and Their Association with Response to Radiotherapy in Moroccan Patients with Nasopharyngeal Carcinoma. *Asian Pac J Cancer Prev* 2023;24(1):93-9.
134. Benzeid R, Ghibid A, Tawfik N, Benchakroun N, Bendahhou K, Benider A, et al. Association between single nucleotide polymorphisms in DNA repair genes and the efficacy of radiotherapy in nasopharyngeal carcinoma patients. *Contemp Oncol.* 2023;27(1):28-34.
135. Wang J, Guo C, Gong X, Ao F, Huang Y, Huang L, et al. The impacts of genetic polymorphisms in genes of base excision repair pathway on the efficacy and acute toxicities of (chemo) radiotherapy in patients with nasopharyngeal carcinoma. *Oncotarget.* 2017;8(45):78633-41.
136. Gandhi D, Chepeha D, Miller T, Carlos R, Bradford C, Karamchandani R, et al. Correlation between initial and early follow-up CT perfusion parameters with endoscopic tumor response in patients with advanced squamous cell carcinomas of the oropharynx treated with organ-preservation therapy. *Am J Neuroradiol.* 2006;27(1):101-6.
137. Zhao Y, Shen L, Huang X, Jing D, Huang D, Fu J, et al. High expression of Ki-67 acts a poor prognosis indicator in locally advanced nasopharyngeal carcinoma. *Biochem Biophys Res Commun.* 2017;494(1-2):390-6.

